The TAXUS Element Paclitaxel-Eluting Coronary Stent System for use on diabetic patients being treated for coronary artery disease has received CE Mark approval in the European Union.

Boston Scientific Corporation’s third-generation drug-eluting stent technology, TAXUS Element Stent System, incorporates a platinum chromium alloy with an innovative stent design and an advanced catheter delivery system.

The company plans to launch the TAXUS Element Stent System next month in the European Union and other CE Mark countries.

The company also expects US Food and Drug Administration approval for the TAXUS Element Stent System in mid-2011.